Its increasing popularity is reflected by a steadily rising impact factor.doi:10.1038/bjc.1980.270WilkinsonPNature Publishing GroupBritish Journal of Cancer
The costs of both newly approved, and established anticancer drugs have risen dramatically in the past decade, to the point where the costs of such treatments are becoming unsustainable. In this perspective, the authors outline the extent of this problem
and drug resistance. Severe oxidative damage is a general consequence of cancer cell responses to treatment and may cause cancer cell death or severe adverse effects. To maintain their longevity, cancer cells can rescue redox balance and enter a state of resistance to anticancer drugs. Therefore,...
Our recent scoping review on end-of-life anticancer treatment analyzes the methodologies and outcomes related to the publications on anticancer drugs during the end of life [21]. Fundamental methodological attributes of these publications were outlined, particularly in terms of determining treatment ...
targeting the GSH/GSSG system may represent an advantageous approach to enhancing oridonin sensitivity and overcoming drug resistance in cancer cells. Platinum compounds are among the most widely used chemotherapy drugs for various types of cancers; however, multidrug resistance is the main barrier preven...
4. Potential anticancer drugs for COVID-19 4.1. Ruxolitinib Ruxolitinib is a potent orally bioavailable Janus kinase (JAK) 1 and JAK2 inhibitor indicated for various myeloproliferative malignancies including myelofibrosis and polycythemia vera [3,198,200]. These neoplasms, alongside with the acute myelo...
Magnetic nanocatalysts Heterocyclic compounds Anticancer drugs Fenton reaction Cancer therapy Introduction Catalysts are widely used in the production of chemicals [1], [2] and pharmaceutical ingredients [3], [4]. A large number of products require the application of catalysts; where, it has been es...
[101]. When these nanocarriers, loaded with anti-tumor drugs, reach the tumor site, the unique conditions of the tumor microenvironment allow for precise drug release. This targeted approach reduces the impact on normal tissues, thereby enhancing treatment specificity. By controlling the timing and ...
Agents that target tumour-supportive cellular machineries, such as the proteasome, heat shock protein complexes and proteins involved in chromatin modifications, are emerging as a new wave of anticancer drugs. Here, Dobbelstein and Moll provide their per
Chitosan nanoparticles (NPs) are well-recognized as promising vehicles for delivering anticancer drugs due to their distinctive characteristics. They have the potential to enclose hydrophobic anticancer molecules, thereby enhancing their solubilities, pe